Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
US Army
Dow
Johnson and Johnson
Express Scripts
Cerilliant
UBS
Julphar
Novartis
Harvard Business School

Generated: January 20, 2018

DrugPatentWatch Database Preview

ABBVIE Company Profile

« Back to Dashboard

Summary for ABBVIE
International Patents:1454
US Patents:89
Tradenames:78
Ingredients:65
NDAs:90
Drug Master File Entries: 1

Drugs and US Patents for ABBVIE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Abbvie SYNTHROID levothyroxine sodium TABLET;ORAL 021402-003 Jul 24, 2002 AB1,AB2 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie CHOLOXIN dextrothyroxine sodium TABLET;ORAL 012302-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 021015-001 Feb 28, 2000 AB1 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie CALCIJEX calcitriol INJECTABLE;INJECTION 018874-002 Sep 25, 1986 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie SYNTHROID levothyroxine sodium TABLET;ORAL 021402-006 Jul 24, 2002 AB1,AB2 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-004 Jul 28, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ABBVIE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie CALCIJEX calcitriol INJECTABLE;INJECTION 018874-002 Sep 25, 1986 ➤ Subscribe ➤ Subscribe
Abbvie MAVIK trandolapril TABLET;ORAL 020528-003 Apr 26, 1996 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020708-001 Mar 7, 1997 ➤ Subscribe ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020708-001 Mar 7, 1997 ➤ Subscribe ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 ➤ Subscribe ➤ Subscribe
Abbvie OMNICEF cefdinir CAPSULE;ORAL 050739-001 Dec 4, 1997 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT-PED leuprolide acetate INJECTABLE;INJECTION 020263-002 Apr 16, 1993 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-001 Dec 22, 1995 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-002 May 30, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 6/19/2014
➤ Subscribe Gel 1.62% (1.25 g and 2.5 g packets) ➤ Subscribe 6/19/2013
➤ Subscribe Capsules 100 mg ➤ Subscribe 10/31/2012
➤ Subscribe Gel 1.62% ➤ Subscribe 4/6/2012
➤ Subscribe Tablets 100 mg ➤ Subscribe 12/21/2010
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 12/6/2010
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 5/10/2010
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 9/2/2009
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 9/1/2009
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 8/12/2009
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 8/4/2009
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 12/23/2008
➤ Subscribe Gel Metered-dose Pump 1% ➤ Subscribe 12/19/2008
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 11/28/2008
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 10/14/2008
➤ Subscribe Capsules 4 mcg ➤ Subscribe 8/25/2008
➤ Subscribe Tablets 48 mg ➤ Subscribe 7/1/2008
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2/20/2008
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 11/9/2007
➤ Subscribe Tablets 145 mg ➤ Subscribe 10/19/2007
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 7/24/2007
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2/24/2006
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 5/27/2005
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2/8/2005
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 10/4/2004
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 5/3/2004

Non-Orange Book US Patents for ABBVIE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,937,150 Anti-viral compounds ➤ Subscribe
8,716,454 Solid compositions ➤ Subscribe
9,394,279 Anti-viral compounds ➤ Subscribe
7,521,068 Dry powder aerosols of nanoparticulate drugs ➤ Subscribe
6,162,443 Container for an inhalation anesthetic ➤ Subscribe
6,406,715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles ➤ Subscribe
6,677,492 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid ➤ Subscribe
6,472,529 Retroviral protease inhibiting compounds ➤ Subscribe
8,332,661 Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices ➤ Subscribe
9,452,194 Methods for treating HCV ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ABBVIE Drugs

Supplementary Protection Certificates for ABBVIE Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/010 Ireland ➤ Subscribe PRODUCT NAME: OMBITASVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115
2017 00049 Denmark ➤ Subscribe PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728
2017015 Lithuania ➤ Subscribe PRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205
2015 00013 Denmark ➤ Subscribe PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150115
12/008 Ireland ➤ Subscribe PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
2013 00053 Denmark ➤ Subscribe PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
/2000 Austria ➤ Subscribe PRODUCT NAME: EPROSARTAN, AUCH IN FORM PHARMAZEUTISCH VERTRAEGLICHER SALZE WIE EPROSARTAN MESYLAT; NAT. REGISTRATION NO/DATE: 1-22115, 1-22114, 1-22117 19970930; FIRST REGISTRATION: DE 39573.00.00 - 39573.02.00 19970417
99C0030 Belgium ➤ Subscribe PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
90012-9 Sweden ➤ Subscribe PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119
09/010 Ireland ➤ Subscribe PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/08/491/001-EU/1/08/491/080 20090116; FIRST REGISTRATION NO/DATE: 58935 01 58935 02 58935 03 58935 04 20081028
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Medtronic
Fuji
Johnson and Johnson
Baxter
Teva
Chubb
Deloitte
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot